BRISBANE, Calif. — November 18, 2025 — Leads & Copy — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. EST.
A live webcast of the discussion will be available in the Events section of the Day One Media & Investors page. An archived replay of the webcast will be available for 30 days following the live event.
Day One Biopharmaceuticals is dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with clinical oncologists, families, and scientists to identify, acquire, and develop targeted cancer treatments. The company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.
Day One is based in Brisbane, California.
The company uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) to disseminate news and announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with disclosure obligations under Regulation FD.
Contact:
Day One Media
Laura Cooper, Head of Communications
media@dayonebio.com
Day One Investors
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
Source: Day One Biopharmaceuticals, Inc.
